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Introduction: Patients with peripheral arterial disease (PAD) have increased mortality from cardiovascular events
compared with age and sex matched controls Platelets play a major role in atherosclerosis and thrombotic vascular events.
Platelet reactivity is increased in patients with PAD compared with healthy controls. We aimed to determine the
relationship, if any, between platelet activation and severity of disease.
Methods and Results: One hundred eighty-two patients with intermittent claudication (IC) or subcritical limb ischemia
(SLI), defined as the presence of rest pain or ulceration, had the following investigations performed: platelet P-selectin
expression and bound fibrinogen by flow cytometric analysis and platelet aggregation using the rapid platelet function
assay with arachidonic acid (AA) and thrombin receptor activation peptide (TRAP) as agonists. Patients with SLI
compared with IC had significantly enhanced ADP stimulated P-selectin expression (median 42.45% [inter-quartile range
33.32% to 58.5%] vs 35.2% [26.07% to 46.32%], P  .002) and bound fibrinogen (73.7% [54.3% to 83.2%] vs 63.7%
[43.8% to 76.5%], P  .001). TRAP stimulated aggregation was higher (207 [153 to 238] PAU vs 183[155 to 199]
PAU, P  .04) but AA mediated aggregation was not significantly different. An ankle-brachial pressure index (ABPI) of
less than 0.6 was associated with increased ADP stimulated P-selectin and bound fibrinogen (P < .05). ABPI correlated
inversely with ADP stimulated P-selectin expression (r  0.228, P  .003), ADP stimulated fibrinogen binding (r 
0.156, P  .043) and TRAP stimulated aggregation (r  0.179, P  .04).
Conclusion:We have demonstrated for the first time that progression of severity of PAD is not only reflected by symptoms,
signs, and ABPI but also by increased platelet activity as assessed by both flow cytometry and aggregation. As patients
with more severe PAD have increased cardiovascular mortality, our findings suggest that new strategies for platelet
inhibitory therapy are indicated in these patients. ( J Vasc Surg 2007;46:485-90.)Peripheral arterial disease (PAD) is common, with a
prevalence of both symptomatic and asymptomatic disease
estimated at 16% in adults over the age of 55.1,2 Patients
diagnosed as having PAD have a two- to three-fold in-
creased risk of cardiovascular and cerebrovascular mortality
when compared with an age and sex matched group with-
out PAD.3,4 Thus, the first line treatment of patients with
PAD is directed at cardiovascular risk factor manage-
ment.5,6 The major risk factors for both cardiovascular
disease and peripheral vascular disease are well established
and include cigarette smoking, dyslipidaemia, hyperten-
sion, and diabetes. In addition tomanagement of these, it is
recommended that all patients are prescribed anti-platelet
therapy.
Abnormal platelet function has been implicated in the
development and progression of atherosclerosis, as well as
in the pathogenesis of acute cardiac ischemic events.7 Plate-
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doi:10.1016/j.jvs.2007.05.039let activation is increased in patients with lower limb isch-
emia compared with healthy controls suggesting an under-
lying prothrombotic state.8-11 The antithrombotic trialist
collaboration meta-analysis has shown that anti-platelet
therapy reduces serious adverse vascular events by 23% in
patients with peripheral arterial disease (PAD).12 PAD
exists as a spectrum of disease ranging from asymptomatic
to severe limb ischemia. The severity of disease is related to
overall survival.
Patients with more severe PAD, as assessed by symp-
toms or the ankle brachial pressure index (ABPI) have
reduced survival. In the Edinburgh Artery Study, almost
20% of patients with intermittent claudication had died
within 5 years, 13.7% from cardiovascular causes.13 With
more severe limb ischemia, patients may present with pain
at rest, ulceration, or gangrene. The present of these symp-
toms is associated with an increased cardiovascular mortal-
ity rate.14
In addition to utility in the diagnosis of PAD, the ABPI
has been shown in many studies to be a good predictor of
future cardiovascular events.15-18 This association is inde-
pendent of the metabolic syndrome and other major car-
diovascular risk factors.19 Significant linear trends have
been shown across ABPI categories and cardiovascular
outcome.15,17,18 In particular, an ABPI less than 0.6 has
consistently been shown to be associated with increased
mortality.
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creased in patients with more severe peripheral arterial
disease. The aim of this study was to determine the rela-
tionship between platelet activation in vivo and reactivity ex
vivo as assessed by flow cytometry markers of activation and
aggregation and severity of PAD in terms of symptoms and
the ankle brachial pressure index.
MATERIALS AND METHODS
Consecutive consenting patients who had intermittent
claudication (n  90) or severe limb ischemia (n  92)
characterized by the presence of rest pain or ulceration were
recruited from the claudication clinic and the vascular unit,
respectively. Patients with claudication had chronic, stable
intermittent claudication for at least 6 months and had not
undergone any prior intervention. The study protocol was
approved by the relevant research ethics committee.
Risk factors were managed as recommended by the
Scottish Intercollegiate Guideline Network (SIGN) guide-
lines.5 All patients were already prescribed 75 mg daily of
aspirin and statin therapy of at least 6 weeks duration. Statin
therapy consisted of 40mg of simvastatin or pravastatin and
10 mg of atorvastin, depending on individual general prac-
titioners prescribing practice. Comorbidities, smoking his-
tory, and ankle brachial pressure indices were documented.
Exclusion criteria. Patients with diabetes, acute limb
ischemia, active infection, those on clopidogrel, warfarin,
nonsteroidal anti-inflammatory drugs, and those unable to
give informed consent were excluded.
Study design. Blood samples were taken by a 21-
gauge needle from the ante-cubital without the use of
tourniquet from fully rested patients. Blood samples were
collected in 3.2% citrate vacutainers for flow cytometry and
platelet aggregation. Ultegra rapid platelet function anal-
yser (RPFA) was performed within 15 minutes of blood
drawing. The following analyses were performed:
Whole blood flow cytometry (Coulter Epics XL-MCL
Flow Cytometer (Beckman Coulter Inc, Calif ): The per-
centage of platelets expressing P-selectin (CD62P) and
bound fibrinogen on platelets with and without ex vivo
Table I. Patient demographics
Intermittent
Median age :
(range)
Male:female
Hypertension (%)* 6
Coronary artery disease (%)† 2
Body mass index (median, interquartile range) 2
Current (%) 4
Reformed smoker (%): (1 year abstinence) 4
Beta-blockers 1
Ca channel blockers 2
ACE inhibitors 1
*Hypertension was defined as a systolic blood pressure greater than 140 m
†Angina, myocardial infarction, previous revascularisation.stimulation with ADP (1105 mol/L) in diluted wholeblood samples was measured, as previously described by
our laboratory.9,21,22
Platelet aggregation was assessed using the RPFA (Ac-
cumetrics, San Diego, Calif). This is a well validated, point
of care; whole blood cartridge based turbidimetric optical
detection system, which assesses the ability of activated
platelets to bind fibrinogen coated micro-beads contained
within the cartridge test wells. Fibrinogen-coated micro-
beads agglutinate in whole blood in proportion to the
number of available GPIIb/IIIa receptors, causing an in-
crease in light transmittance.23,24 The test has been shown
to correlate well with conventional platelet aggregom-
etry.25 The agonist in the RPFA-TRAP assay is thrombin
receptor activating peptide (TRAP) and in the RPFA-ASA
assay is arachidonic acid (AA). The analyser measures the
change in the optical signal and reports it as platelet aggre-
gation units (PAU) for the RPFA-TRAP assay and aspirin
reaction units (ARU) for the RPFA-ASA. An ARU of
greater than or equal to 550 indicates a nonresponse to
aspirin. Inter-assay variation was 5.8% for RPFA-ASA and
5.0% for RPFA-TRAP.26,27
Statistical analysis. Based on a 10% anticipated in-
crease in platelet aggregation (TRAP) in patients with
subcritical limb ischemia compared with claudication, at
90% power, 0.05 significance, 90 patients per group were
required.26
Calculations were performed with SPSS for Windows
version 13.0 statistical software (SPSS, Chicago, Ill). The
results of platelet activity markers and aggregation between
the two cohorts were compared using theMannWhitneyU
test. Spearmans correlation coefficient was used to deter-
mine the relationship between ABPI and platelet activity.
RESULTS
Patient characteristics. One hundred eighty-two
patients were recruited for the study. Clinical character-
istics of the study population are summarized in Table I.
There was no difference between the two groups. The
ABPI s of the patients included in this study ranged from
dication N  90 Severe limb ischemia N  92 P
.5 69 .28
97 48-88
26 57:35 .26
%) 56.7 (51%) .12
.3%) 28.3 (26%) .75
-30) 25 (21-29) .05
%) 48 (53%) .35
%) 35 (38%)
%) 23 (25%) .05
%) 28 (30%)
%) 27 (29%)
and/or diastolic greater than 90 mm Hg.clau
71
43-
64:
1 (68
7 (30
7 (25
1 (47
3 (48
5 (16
6 (28
9 (210.34 to 0.88.
ression
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selectin expression and bound fibrinogen were similar in
patients with intermittent claudication and subcritical limb
ischemia. The ABPI did not correlate with unstimulated P-
selectin (r  0.117, P  .132) or fibrinogen binding (r 
0.71,0.236). ADP stimulated platelet P-selectin expression
and fibrinogen bindingwere significantly increased in patients
with subcritical limb ischemia compared to patients with in-
termittent claudication (Table II) (P  .01).
The ABPI correlated with ADP stimulated P-selectin
expression (r  0.228, P  .003) and ADP stimulated
fibrinogen binding ( r 0.156, P  .043) (Figs 1 and 2).
ADP stimulated P-selectin expression was significantly in-
creased in patients with an ABPI less than compared with
greater than 0.6. (34.2 [27 to 40.4] vs 42.3 [29.7 to 56.25]
P  .003). Similarly, ADP stimulated bound fibrinogen
was increased in patients with an ABPI 0.6 compared
with those with ABPI 0.6 9 (63.9 [41.9 to 76.9] vs 73.0
[55.05 to 82.45], P  .02).
Platelet aggregation. AA mediated platelet aggrega-
tion was not statistically different between the two groups
and did not correlate with the ABPI (r 0.059, P .51)
Table II. Ankle brachial pressure index (ABPI) and platel
severe limb ischemia
Intermittent claudicatio
ABPI 0.61 (0.55-0.74
P-selectin* 0.61(0.38-1.01
P-selectin (ADP)* 35.2 (26.07-46.
Fibrinogen binding* 1.68 (.58-4.47)
Fibrinogen binding* ( ADP) 63.7 (43.8-76.5
Results are expressed as medians and interquartile ranges.
*P-selectin and fibrinogen binding are expressed as percentage platelet exp
†P value: Mann-Whitney U test.
0.800.600.400.20
80
60
40
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0
% Platelets
ABPI
Fig 1. Spearmans correlation coefficient between ADP-stimulate
P-selectin expression and the ankle brachial pressure index (ABPI).(Fig 3). TRAP stimulated platelet aggregation was sig-nificantly increased in patients with subcritical limb isch-
emia (Fig 4, P  .05). Overall, 11% of the patients had a
ARU greater than 550, suggesting an inadequate response
to aspirin. Patients with severe limb ischemia were over-
represented in this group (14% vs 5%, P  .05).
The ABPI showed an inverse correlation with TRAP
mediated aggregation (r 0.179, P  .04) (Fig 5).There
was no difference in either AA or TRAP mediated aggrega-
tion between patients with an ABPI less than or greater
than 0.6.
Correlation between platelet assays. ADP stimu-
lated P-selectin expression and bound fibrinogen were cor-
related (r  0.61, P  .001) as were AA mediated aggre-
gation and ADP stimulated P-selectin expression (r 0.22,
P  .009). There was no difference in the flowcytometry
results between patients who were aspirin responders and
nonresponders.
DISCUSSION
This is the first study to show that platelet activation as
assessed by aggregation and flow cytometry is significantly
enhanced in patients with subcritical limb ischemia com-
nction tests in patients with intermittent claudication and
 90) Severe limb ischemia (N  92) P†
0.40 (0.34-0.50) .001
0.70 (.36-1.28) .78
45.05 (34.12-58.8) .001
1.68 (.58-4.47) .42
74.55 (59.2-85.35) .001
.
0.800.600.400.20
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Fig 2. Spearmans correlation coefficient between ADP-stimulate
fibrinogen binding and the ankle brachial pressure index (ABPI).et fu
n (N
)
)
32)
)pared with patients with intermittent claudication, despite
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shown that platelet activation is increased in patients with
PAD compared with healthy controls.7-9,11 Furthermore,
we showed previously a tendency for increased P-selectin
expression but no change in fibrinogen binding in patients
with more severe arterial disease, although that study was
not powered to assess differences in platelet function ac-
cording to the severity of disease and did not assess platelet
aggregation.9 To assess platelet function comprehensively
both flow cytometric parameters and aggregation should
be measured, in view of the range of pathways involved in
platelet activation.8,28,29 The current study supports the
Severe limb ischemiaIntermittent claudication
700
600
500
400
300
200
100
0
ARU
*
Fig 3. Arachadoinc acid (AA) mediated platelet aggregation.
Data presented as box-plots-line in center of box represents the
median value; the box represents the inter-quartile range and the
whiskers represent the range.*P  .05, Mann-Whitney U test.
Severe limb ischemiaIntermittent claudication
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Fig 4. Thrombin receptor activating peptide (TRAP) stimulated
platelet aggregation. Data presented as box-plots-line in center of
box represents the median value; the box represents the inter-
quartile range and the whiskers represent the range.**P  .05,
Mann-Whitney U test.use of such an approach.Platelet aggregation as assessed by TRAP as agonist
significantly increased in patients with subcritical limb isch-
emia compared with those with intermittent claudication.
There was a tendency for increased AA mediated aggrega-
tion and also a higher proportion of nonresponders to
aspirin in the severe limb ischemia cohort (5% vs 14%).
We have previously shown that unstimulated platelet
P-selectin expression and bound fibrinogen are increased in
patients with PAD compared with healthy controls. In a
small cohort of 20 patients with subcritical limb ischemia
and tissue loss, we found that ADP stimulated fibrinogen
binding but not unstimulated fibrinogen binding was sig-
nificantly reduced compared with healthy controls.9 Many
of these patients had diabetes, and it was felt that the
presence of infection, poor diabetic control, and specific
diabetic therapy may have accounted for this finding. Thus,
we actively excluded diabetic patients from this current
study. A control groupwas not included in this study due to
the inability to standardize for variables, which may affect
platelet function such as statin and aspirin therapy and
smoking. The primary aim of the current study was not
to compare PAD and controls, for which we already have
published data, but to look for a relationship between
platelet activation measures and severity of vascular dis-
ease. Now, we demonstrate significantly increased ADP-
stimulated P-selectin expression and bound fibrinogen in
patients with more severe ischemia but no difference
when platelets are studied in the unstimulated state. Our
findings are consistent with those of Tan et al, who found
significantly increased platelet microparticles in patients
with severe limb ischemia compared with those with
intermittent claudication.30
This increase in platelet reactivity is consistent with the
hypothesis that circulating platelets are more reactive in
0.800.600.400.20
400
350
300
250
200
150
100
50
PAU
ABPI
Fig 5. Spearmans correlation coefficient between thrombin re-
ceptor activating peptide (TRAP) stimulated platelet aggregation
and ankle brachial pressure index (ABPI).patients with more severe PAD despite anti-platelet therapy
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of thrombus formation in response to an in vivo stimulus,
typically as plaque rupture.
The patient cohorts were well matched apart from the
severity of PAD as reflected by the significantly lower ABPI
in patients with subcritical limb ischemia. It is known that,
overall, patients with an ABPI less than 0.6 have reduced
survival.18 In this study, 37 patients in the claudication
group had an ABPI less than 0.6. We have shown now that
ex vivo ADP stimulated P-selectin expression and bound
fibrinogen are increased in patients with an ABPI less than
0.6. Significant inverse correlations were observed across
the spectrum of ABPIs included in this study, ADP stimu-
lated platelet expression, and TRAP mediated aggregation.
This is consistent with the observation that the presence of
small platelet aggregates correlates with the ABPI in pa-
tients with PAD and known coronary artery disease.30 We
have shown, as have previous studies, wide variation in the
degree of platelet activation amongst individual patients
and the lack of a clear discrimination between patients with
subcritical limb ischemia, intermittent claudication, and
healthy controls. There appears be no clear “cut-off” value
for P-selectin, fibrinogen binding, or TRAP mediated ag-
gregation, which would indicate the need for alternative or
additional anti-platelet therapy to aspirin 75 mg daily.
However, our findings support the use of more aggressive
platelet suppressive, regimens, such as the addition of clo-
pidogrel, in patients with more advanced PAD. These
patients are known to have reduced survival due to an
increased incidence of thrombotic events such as myocar-
dial infarction and stroke. While the anti-platelet triallest
collaboration has shown the benefit of anti-platelet therapy
in patients with PAD, it should be noted that inmany of the
studies patients were prescribed a variety of anti-platelet
agents. The Clopidogrel versus Aspirin in Patients at Risk of
Ischaemic Events (CAPRIE) trial has shown that clopi-
dogrel is more effective than aspirin in reducing serious
adverse events. In the patients with PAD, clopidogrel
achieved a 23.8% relative risk reduction compared with
aspirin.32 Clopidogrel has been shown to be a more effec-
tive at inhibiting ADP induced platelet activation and flow
cytometry markers of platelet activation.21,33,34 In the
United Kingdom, the National Institute for Clinical Excel-
lence has stated that the cost-effectiveness for clopidogrel
in patients with PAD is not proven.35 Targeting the use of
clopidogrel to patients with more severe disease who have
reduced survival may make this therapy cost-effective.
CONCLUSION
This study has shown that progression of severity of
PAD is not only reflected by symptoms, signs, and ABPI
but also by increased platelet reactivity. This has implica-
tions for therapy. Clinical trials of more aggressive anti-
platelet therapy are indicated in patients with severe PAD as
manifested by the presence of rest pain or ulceration or an
ABPI less than 0.6.20, 31The research fellow Sriram Rajagopalan was sponsored
by a grant from the Scottish Chief Scientist Office. Ian
McKay was sponsored by a BHF project grant. The statis-
tical advice was given by Mr G. Prescott and Mr E. Amalraj
(Department of Public Health, University of Aberdeen).
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